reviewed april 2026|next review october 2026|88 physicians psi has verified|19 published studies
Triptorelin
Triptorelin is a synthetic decapeptide GnRH agonist with 100-fold greater receptor affinity than native GnRH, FDA-approved as Trelstar for advanced prostate cancer and available in 1, 3, and 6-month depot formulations.
Evidence landscape: 19 published studies
19 published items indexed for this slug. The broader triptorelin literature is substantially larger under generic name searches. A well-established GnRH agonist with multiple depot formulations.
- 4 Human
- 15 Animal
FDA-approved prescription medicine in the United States as Trelstar for palliative treatment of advanced prostate cancer. Available in three depot formulations.
Phase III trials demonstrate 95%+ castration rates maintained through 48 weeks. Three depot formulations (1, 3, and 6-month) each independently validated.
One of several FDA-approved GnRH agonists (alongside leuprolide, goserelin, nafarelin). Distinguished by 100-fold GnRH receptor potency and triple depot option range.
PSI Assessment
A single dose of triptorelin causes a testosterone surge. Continuous dosing suppresses testosterone to near zero. That paradox is the defining pharmacological feature of every GnRH agonist, and triptorelin is one of the most potent in the class, with 100-fold greater affinity for the GnRH receptor than the native hormone. FDA-approved as Trelstar for advanced prostate cancer, it is also used in IVF protocols. The bodybuilding community has discussed single-dose triptorelin for restarting the hormonal axis after anabolic steroid cycles, an application based on one case report and carrying the risk of chemical castration if dosed incorrectly.
100-fold greater GnRH receptor affinity than the native hormone. Paradoxical pharmacology: a single dose stimulates, continuous dosing suppresses.
The mechanism is GnRH receptor super-agonism. Triptorelin's 100x potency means it saturates GnRH receptors more completely than native GnRH. Acute exposure triggers an LH and FSH surge (the flare). Sustained exposure causes complete receptor downregulation and desensitization, suppressing testosterone to below 20 ng/dL within 2-4 weeks. Available as 1-month, 3-month, and 6-month depot injections, the depot formulations provide continuous exposure that maintains the suppressive state.
What the evidence supports
FDA-approved with extensive clinical data for prostate cancer. The GnRH agonist mechanism is thoroughly characterized with 100-fold greater receptor affinity than native GnRH. Chemical castration is reliable, with 95%+ patients achieving castrate testosterone levels. Available in 1, 3, and 6-month depot formulations providing dosing flexibility.
What is not yet established
Whether single-dose triptorelin safely restarts the HPG axis after anabolic steroid use, based on one case report only. The risk-benefit ratio of using a chemical castration drug for hormone optimization. Whether triptorelin offers any advantage over hCG or clomiphene for post-cycle recovery. Head-to-head survival comparisons with other GnRH agonists.
Research Evidence
The findings below cover the approved indications and the controversial post-steroid-cycle application.
Evidence by condition
Evidence dimensions across triptorelin indications. Prostate cancer and IVF have deep clinical evidence. Post-steroid recovery rests on a single case report with no controlled data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Prostate Cancer | ||||
| IVF / Fertility Protocols | ||||
| Post-Steroid Recovery |
Phase III data demonstrates castration-level testosterone (below 50 ng/dL) achieved in 95%+ of patients, maintained through 48 weeks across all three depot formulations (1-month, 3-month, and 6-month). The 6-month formulation provides the longest dosing interval among GnRH agonist injectables.
The triple depot option range (1, 3, 6 months) distinguishes triptorelin from some other GnRH agonists and allows individualized dosing schedules based on patient preference and clinical need.
In IVF protocols, triptorelin is used for pituitary downregulation before controlled ovarian stimulation. The GnRH agonist long protocol prevents premature LH surges that would cause premature ovulation.
GnRH antagonist protocols have increasingly replaced agonist protocols in modern IVF due to shorter treatment courses, but agonist protocols remain in use. Triptorelin can also be used as an ovulation trigger in antagonist protocols (GnRH agonist trigger).
A single case report describes HPG axis restart after prolonged anabolic steroid use with a single 100 mcg dose of triptorelin. This application has gained attention in the bodybuilding community but rests on one uncontrolled observation.
The risk of chemical castration from incorrect dosing is significant. A full therapeutic dose of triptorelin causes prolonged testosterone suppression. Safer, better-studied alternatives (hCG, clomiphene, enclomiphene) exist for post-cycle hormonal recovery.
4 Human|15 Animal|0 Reviews
View all 19 indexed studiesHow Triptorelin Works
Triptorelin is a synthetic GnRH decapeptide agonist with a D-tryptophan substitution at position 6, conferring 100-fold greater binding affinity for the GnRH receptor compared to native GnRH and resistance to enzymatic degradation.
Triptorelin is a potent synthetic version of GnRH. The hormone that tells your pituitary to release LH and FSH. A single dose causes a surge of these hormones. But if you take it continuously, the pituitary gets overwhelmed and shuts down, eventually stopping hormone production almost completely. This shutdown is the therapeutic goal in prostate cancer.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Triptorelin is a synthetic GnRH decapeptide agonist with 100x potency of native GnRH. Acute administration causes an LH/FSH flare. Sustained exposure causes GnRH receptor downregulation and desensitization, resulting in chemical castration with testosterone levels below 20 ng/dL within 2-4 weeks.
What is Triptorelin being studied for?
Researchers are studying Triptorelin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Triptorelin overall. This means a compound can have human studies for one condition but only animal data for another.
Prostate Cancer
·FDA ApprovedFDA-approved for advanced prostate cancer. Suppresses testosterone to castration levels, removing the hormonal stimulus for prostate cancer growth. Available as 1-month, 3-month, and 6-month depot injections.
Limitations: Initial testosterone flare can temporarily worsen symptoms. Must be combined with anti-androgen therapy during the first weeks. Long-term androgen deprivation carries bone density, metabolic, and cardiovascular risks.
IVF / Fertility Protocols
·FDA ApprovedUsed for pituitary downregulation in IVF protocols and as a GnRH agonist ovulation trigger. Prevents premature LH surges during controlled ovarian stimulation.
Limitations: GnRH antagonist protocols are shorter and increasingly preferred. Risk of ovarian hyperstimulation syndrome requires monitoring.
Post-Steroid Recovery
·PreclinicalA single case report describes HPG axis restart after anabolic steroid use. The bodybuilding community has discussed this application, but it rests on one uncontrolled observation and carries the risk of chemical castration from incorrect dosing.
Limitations: One case report only. No controlled studies. Risk of prolonged testosterone suppression from incorrect dosing. Safer alternatives (hCG, clomiphene) exist and are better studied.
Safety and Regulatory Status
FDA Status: FDA-approved as Trelstar (triptorelin pamoate) for palliative treatment of advanced prostate cancer. Available in 3.75mg (1-month), 11.25mg (3-month), and 22.5mg (6-month) depot formulations.
Prescription status: Prescription-only in the United States. Intramuscular depot injection administered by healthcare professionals.
Class context: Member of the GnRH agonist class alongside leuprolide, goserelin, and nafarelin. All share the paradoxical suppression mechanism.
The primary effect, testosterone suppression, is the therapeutic goal in cancer treatment but a serious risk if used inappropriately. Hot flashes, decreased libido, and bone density loss occur with sustained use. A single inappropriate dose can cause prolonged chemical castration. The initial flare requires anti-androgen co-therapy in prostate cancer patients.
Questions and Comparisons
Questions the evidence raises for a Triptorelin discussion.
Comparison and Related Research
Triptorelin is most often compared with other GnRH agonists (leuprolide, goserelin) and with GnRH antagonists (degarelix, relugolix) which achieve suppression without the initial flare.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Phase III noninferiority trial comparing triptorelin to leuprolide in men with advanced prostate cancer. Triptorelin achieved equivalent testosterone suppression to castrate levels, establishing it as a viable alternative among GnRH agonists for androgen deprivation therapy.Heyns CF et al., 2003 in BJU Int. View on PubMed
- 2.International consensus statement on GnRH agonist use - including triptorelin - for central precocious puberty in children. Summarized evidence on long-term outcomes including final adult height, bone health, and reproductive function after treatment.Carel JC et al., 2009 in Pediatrics. View on PubMed
- 3.One of the earliest clinical reports demonstrating that LHRH agonists could suppress testosterone and inhibit tumor growth in men with prostate cancer. This foundational work helped establish the GnRH agonist class - including triptorelin - as a standard of care for advanced prostate cancer.Tolis G et al., 1982 in Proc Natl Acad Sci U S A. View on PubMed
- 4.Comprehensive review of triptorelin's clinical profile including all available depot formulations (1-month, 3-month, and 6-month). Covered efficacy data, testosterone suppression kinetics, and practical considerations for long-term androgen deprivation therapy in prostate cancer.Merseburger AS et al., 2016 in Adv Ther. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.